|
MechanismLipid modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
100 Clinical Results associated with ReVision Therapeutics, Inc.
0 Patents (Medical) associated with ReVision Therapeutics, Inc.
100 Deals associated with ReVision Therapeutics, Inc.
100 Translational Medicine associated with ReVision Therapeutics, Inc.